Daiichi Sankyo launches new generic drugs

15 December 2014

Japanese pharma major Daiichi Sankyo (TYO: 4568) says its generics subsidiary, Daiichi Sankyo Espha, has launched nine new generic drugs with three new active ingredients

Product names/therapeutic categories

Product name	Therapeutic category	Original brand name
Levofloxacin Tablets 250mg “DSEP”	Broad-spectrum oral antibacterial agent	Cravit tablets 250mg, 500mg, granules 10%
Levofloxacin Tablets 500mg “DSEP”
Levofloxacin Granules 10% “DSEP”
Candesartan Tablets 2mg “DSEP”	Persistent angiotensin II receptor antagonist	Blopress tablets 2,4,8,12
Candesartan Tablets 4mg “DSEP”
Candesartan Tablets 8mg “DSEP”
Candesartan Tablets 12mg “DSEP”
Oxaliplatin IV Infusion Solution 50mg “DSEP”	Anti-malignant tumor agent	Elplat IV Infusion Solution 50mg, 100mg
Oxaliplatin IV Infusion Solution 100mg “DSEP”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK